RETLIRA is a powerful triple-action peptide therapy containing 30mg of Retatrutide, a new-generation weight loss compound targeting:
GLP-1 receptors – reduces appetite and stabilizes blood sugar
GIP receptors – improves insulin sensitivity
Glucagon receptors – boosts fat burning and metabolism
RETLIRA mimics three key metabolic hormones in one weekly injection,
outperforming older GLP-1 options like Semaglutide and Tirzepatide.
High-strength Retatrutide – clinically backed for fat loss & glucose control
Convenient pre-filled 30mg pen
Ideal for those who’ve plateaued on Semaglutide or Tirzepatide
Supports long-term appetite regulation, visceral fat loss, and insulin
improvement
Used in cutting-edge obesity protocols
Triple action. One injection. Total transformation.

Active Ingredient Retatrutide 30mg per pen
Total Volume 3ml (10mg/ml)
Dosing Adjustable dial, 2.5mg–15mg per week
Injection Type Subcutaneous (abdomen, thigh, upper arm)
Use Once per week
Storage Refrigerate unopened (2–8°C). Use within 30 days once opened.
Format Prefilled, dial-dose pen (multi-week use)
One pen lasts 2 to 12 weeks, depending on dosage. Use once weekly on the same day each week.
DOSAGE CALCULATOR – RETRATRUTIDE 
Wee Suggested Volume to Dial (ml @ Effective Dose 10mg/ml)
1–2 2.5mg 0.25ml Intro phase – reduce nausea
3–4 5.0mg 0.5ml Appetite control begins
5–6 7.5mg 0.75ml Fat burn stage
7–8 10.0mg 1.0ml Full therapeutic level
9+ 12.5–15.0mg 1.25–1.5ml Maximum dose